CompletedPhase 1NCT01445522

ABT-888 Plus Metronomic Cyclophosphamide to Treat Cancer

Studying Cerebrotendinous xanthomatosis

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
National Cancer Institute (NCI)
Principal Investigator
Shivaani Kummar, M.D., M.D
National Cancer Institute (NCI)
Intervention
ABT-888(drug)
Enrollment
35 target
Eligibility
18-110 years · All sexes
Timeline
20082012

Study locations (2)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT01445522 on ClinicalTrials.gov

Other trials for Cerebrotendinous xanthomatosis

Additional recruiting or active studies for the same condition.

See all trials for Cerebrotendinous xanthomatosis

← Back to all trials